Last updated on December 25, 2025
PETALING JAYA, 26 November 2025 — Sunzen Group Berhad posted a strong turnaround for its first quarter ended 30 September 2025 (Q1 FY2026), with profit before tax (PBT) rising fourfold to RM3.69 million, supported by stronger contributions from its loan financing, human health, and medical devices segments.
Despite a 14.29% year-on-year (YoY) drop in revenue to RM19.68 million due to weaker edible bird’s nest export sales, PBT surged from RM0.86 million a year earlier on improved operating efficiency and segmental profitability.
The Group said the medical devices and services division, consolidated since December 2024, also contributed positively to earnings, alongside a reduction in operating expenses in the human health segment.
Quarter-on-quarter rebound: PBT reverses from RM0.53 million loss
On a quarter-on-quarter (QoQ) basis, Sunzen delivered a sharp recovery, with revenue rising 31.34% from RM14.98 million in Q4 FY2025. PBT rebounded from a RM0.53 million loss, which had included a one-off RM2.97 million bad debt write-off, to a profit of RM3.69 million in Q1 FY2026.
Segmental performance
| Segment | Revenue (RM million) | YoY Change | PBT / (LBT) (RM million) | Notes |
|---|---|---|---|---|
| Human Health (Ecolite) | 13.05 | -26.06% | (0.40) | Improved cost discipline; lower operating expenses narrowed losses |
| Medical Devices & Services (Eye Nation Medical) | 1.99 | N/A | 0.25 | First full consolidation; higher demand for ophthalmic equipment & services |
| Loan Financing | 4.64 | +41.90% | 3.45 | Strong SME financing demand; stable loan performance |
| Group Total | 19.68 | -14.29% | 3.69 | Fourfold YoY surge despite lower topline |
Managing Director: “Earnings momentum reflects strength of core businesses”
Group Managing Director Teo Yek Ming said the latest results demonstrate resilience across Sunzen’s diversified portfolio.
“The rebound in profitability and the strong QoQ turnaround demonstrate the effectiveness of our operational adjustments, particularly in Human Health, while the Loan Financing and Medical Devices divisions continue to provide consistent earnings momentum,” he said.
He added that the Group will continue scaling high-growth categories and enhancing distribution and product capabilities.
Outlook: FMCG expansion, AI adoption, and export recovery
Sunzen said it remains cautiously optimistic heading into the next quarter:
- Loan financing demand remains stable despite a softer economic backdrop
- Ecolite expects stronger Q2 seasonal demand, with PP bottle bird’s nest drinks now in production
- First export shipment to a new customer in Cambodia is expected by December
- Negotiations with retail chains continue as part of its FMCG expansion
- AI-assisted skin analysis and product personalisation will support customer retention
In the Medical Devices division, rising ophthalmic demand and increased government healthcare allocations (+2.76% YoY) will support the segment’s growth trajectory.
Dividend declared
The Board declared an interim single-tier dividend of RM0.002 per share for FY2026, payable on 12 January 2026. The entitlement date is 15 December 2025.
